Revvity reported third-quarter 2026 revenue of $729 million and adjusted EPS of $1.38, both significantly exceeding analyst estimates. The company achieved a major acceleration in pro forma organic revenue growth to 7%, far outpacing the anticipated 0.3%, as broad-based momentum and improved execution across both segments allowed for faster-than-expected backlog conversion.
Key Highlights
- Reported revenue of $729 million beat the $700.9 million consensus, while pro forma revenue excluding the China IDX business was $710 million.
- Adjusted EPS of $1.38 exceeded the $1.29 estimate, reflecting strong operating leverage and transformation benefits.
- The Life Sciences segment generated $380 million in revenue with 9% pro forma organic growth, supported by resilient demand in drug discovery end-markets.
- Management raised its full-year 2026 pro forma adjusted EPS guidance to a range of $5.40-$5.45.